Teva to continue selling Viagra generic in Russia

7 November 2011

Israel-basedTeva Pharmaceutical Industries (Nasdaq: TEVA) managed to avoid a high-profile confrontation in the Russian pharmaceutical market, regarding its recent launch of a generic of pharma behemoth Pfizer’s (NYSE: PFE) blockbuster erectile dysfunction drug Viagra (sildenafil), in the local market.

In August this year, Teva officially launched its new drug, which is known as Dynamico and is based on sildenafil, an active ingredient of Viagra, in the Russian market, thereby, according to Pfizer, violated its exclusive patent on Viagra. Pfizer said that it has a patent in Russia which protects its exclusive right to use sildenafil in the treatment of erectile dysfunction in men, which is valid until May 13, 2014.

After this the US company started preparations for judicial proceedings against Teva in the Moscow Arbitration Court, which was scheduled for November 21. Pfizer has already won a patient dispute with Teva in the USA, gaining protecting for Viagra through October 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK